Human papillomavirus 16 E6, L1, L2 and E2 gene variants in cervical lesion progression

Virus Research

Volumn 131, Issue 1, 2008, Pages 106-110

  Lee, K ^a   Magalhaes, I ^b   Clavel, C ^c   Briolat, J ^c   Birembaut, P ^c   Tommasino, M ^d   Zehbe, I ^a  

^a Regional Cancer Care   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HÔPITAL MAISON BLANCHE   (France)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cervical lesion progression; E2; E6; Human papillomavirus 16; L1; L2; Variants

Indexed keywords

ARTICLE; DISEASE COURSE; DISEASE SEVERITY; E2 GENE; E6 GENE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; L1 GENE; L2 GENE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UTERINE CERVICITIS; VIRUS GENE; VIRUS GENOME;

DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 36849007486     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.08.003     Document Type: Article

References (27)

1. Asadurian, Y., Kurilin, H., Lichtig, H., Jackman, A., Gonen, P., Tommasino, M., Zehbe, I., Sherman, L., in press. HPV16 E6 natural variants exhibit different activities in inhibition of serum- and calcium-induced differentiation of primary human keratinocytes, J. Med. Virol.
2. Bernard H.U. The clinical importance of the nomenclature Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J. Clin. Virol. 32 Suppl. 1 (2005) S1-S6
3. Chakrabarti O., Veeraraghavalu K., Tergaonkar V., Liu Y., Androphy E.J., Stanley M.A., and Krishna S. Human papillomavirus type E6 amino acid 83 variants enhance E6-mediated MAPK signalling and differentially regulate tumorigenesis by notch signalling and oncogenic Ras. J. Virol. 78 (2004) 5934-5945
4. Chaturvedi A.K., Brinkman J.A., Gaffga A.M., Dumestre J., Clark R.A., Braly P.S., Dunlap K., Kissinger P.J., and Hagensee M.E. Distribution of human papillomavirus type 16 variants in human immunodeficiency virus type 1-positive and -negative women. J. Gen. Virol. 85 (2004) 1237-1241
5. Chen Z., Terai M., Fu L., Herrero R., DeSalle R., and Burk R.D. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J. Virol. 79 (2005) 7014-7023
6. Grodzki M., Besson G., Clavel C., Arslan A., Franceschi S., Birembaut P., Tommasino M., and Zehbe I. Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol. Biomark. Prev. 15 (2006) 820-822
7. Gustafsson L., and Adami H.-O. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br. J. Cancer 60 (1989) 132-141
8. Kammer C., Tommasino M., Syrjanen S., Delius H., Hebling U., Warthorst U., Pfister H., and Zehbe I. Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease. Br. J. Cancer 86 (2002) 269-273
9. Mitchel M.F., Hittelman W.N., and Hong W.K. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol. Biomark. Prev. 3 (1994) 619-626
10. Moreno V., Munoz N., Bosch F.X., de Sanjose S., Gonzalez L.C., Tafur L., Gili M., Izarzugaza I., Navarro C., Vergara A., et al. Risk factors for progression of cervical intraepithelial neoplasia grade III to invasive cervical cancer. Cancer Epidemiol. Biomark. Prev. 4 (1995) 459-467
11. Ortiz M., Torres M., Munoz, Fernandez-Garcia L.E., Canals J., Cabornero A.I., Aguilar E., Ballesteros J., del Amo J., and Garcia-Saiz A. Oncogenic human papillomavirus (HPV) type distribution and HPV type 16 E6 variants in two Spanish population groups with different levels of HPV infection risk. J. Clin. Microbiol. 44 (2006) 1428-1434
12. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12 (1993) 186-192
13. Picconi M.A., Alonio L.V., Sichero L., Mbayed V., Villa L.L., Gronda J., Campos R., and Teyssie A. Human papillomavirus type 16 variants in Quechua aboriginals from Argentina. J. Med. Virol. 69 (2003) 546-552
14. del Refugio Gonzales-Losa M., Laviada Mier y Teran M.A., Puerto Solis M., and Garcia-Carranca A. Molecular variants of HPV16 type 16 among Mexican women with LSIL and invasive cancer. J. Clin. Virol. 29 (2004) 95-98
15. Sathish N., Abraham P., Peedicayil A., Sridharan G., and Chandy G. HPV16 E6 sequence variations in Indian patients with cervical neoplasia. Cancer Lett. 229 (2005) 93-99
16. Seedorf K., Krammer G., Durst M., Suhai S., and Rowekamp W.G. Human papillomavirus type 16 DNA sequence. Virology 145 (1985) 181-185
17. Syrjanen K., Kataja V., and Yliskoski M. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet. Gynecol. 79 (1992) 676-682
18. Terry G., Ho L., and Cuzick J. Analyses of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type. Int. J. Cancer 73 (1997) 651-655
19. Wheeler C.M., Yamada T., Hildesheim A., and Jenison S.A. Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J. Clin. Microbiol. 35 (1997) 11-19
20. Yamada T., Wheeler C.M., Halpern A.L., Stewart A.C., Hildesheim A., and Jenison S.A. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J. Virol. 69 (1995) 7743-7753
21. Yamada T., Manos M.M., Peto J., Greer C.E., Munoz N., Bosch F.X., and Wheeler C.M. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J. Virol. 71 (1997) 2463-2472
22. Yang R., Wheeler C.M., Chen X., Uematsu S., Takeda K., Akira S., Pastrana D.V., Viscidi R.P., and Roden R.B.S. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J. Virol. 79 (2005) 6741-6750
23. Zehbe I., Wilander E., Delius H., and Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58 (1998) 829-833
24. Zehbe I., Voglino G., Delius H., Wilander E., and Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 352 (1998) 1441-1442
25. Zehbe I., Voglino G., Wilander E., Delius H., Marongiu A., Edler L., Klimek F., Andersson S., and Tommasino M. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res. 61 (2001) 608-611
26. Zehbe I., Tachezy R., Mytilineos J., Voglino G., Mikyskova I., Delius H., Marongiu A., Gissmann L., Wilander E., and Tommasino M. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int. J. Cancer 94 (2001) 711-716
27. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 (2002) 342-350